Your browser doesn't support javascript.
loading
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Zhang, Yunlin; Patel, Ruchi P; Kim, Ki Hyun; Cho, Hyungwoo; Jo, Jae-Cheol; Jeong, Seong Hyun; Oh, Sung Yong; Choi, Yoon Seok; Kim, Sung Hyun; Lee, Ji Hyun; Angelos, Mathew; Guruprasad, Puneeth; Cohen, Ivan; Ugwuanyi, Ositadimma; Lee, Yong Gu; Pajarillo, Raymone; Cho, Jong Hyun; Carturan, Alberto; Paruzzo, Luca; Ghilardi, Guido; Wang, Michael; Kim, Soohwan; Kim, Sung-Min; Lee, Hyun-Jong; Park, Ji-Ho; Cui, Leiguang; Lee, Tae Bum; Hwang, In-Sik; Lee, Young-Ha; Lee, Yong-Jun; Porazzi, Patrizia; Liu, Dongfang; Lee, Yoon; Kim, Jong-Hoon; Lee, Jong-Seo; Yoon, Dok Hyun; Chung, Junho; Ruella, Marco.
Affiliation
  • Zhang Y; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.
  • Patel RP; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Kim KH; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.
  • Cho H; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Jo JC; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
  • Jeong SH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, Korea.
  • Oh SY; Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
  • Choi YS; Ajou University Hospital, Suwon, Korea.
  • Kim SH; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
  • Lee JH; Ajou University Hospital, Suwon, Korea.
  • Angelos M; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
  • Guruprasad P; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
  • Cohen I; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.
  • Ugwuanyi O; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Lee YG; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.
  • Pajarillo R; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Cho JH; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.
  • Carturan A; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Paruzzo L; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.
  • Ghilardi G; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Wang M; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.
  • Kim S; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Kim SM; College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Korea.
  • Lee HJ; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.
  • Park JH; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Cui L; Department of Pathology, Immunology and Laboratory Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
  • Lee TB; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.
  • Hwang IS; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Lee YH; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.
  • Lee YJ; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Porazzi P; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.
  • Liu D; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Lee Y; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.
  • Kim JH; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Lee JS; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
  • Yoon DH; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
  • Chung J; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
  • Ruella M; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Mol Cancer ; 22(1): 200, 2023 12 09.
Article in En | MEDLINE | ID: mdl-38066564
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Receptors, Antigen, T-Cell / Receptors, Chimeric Antigen Limits: Humans Language: En Journal: Mol Cancer Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Receptors, Antigen, T-Cell / Receptors, Chimeric Antigen Limits: Humans Language: En Journal: Mol Cancer Year: 2023 Document type: Article